Сравнение

Glepaglutide vs. Terlipressin

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

нет данных

14636-12-5

Молекулярная масса

нет данных

1227.37 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Terlipressin

Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Glepaglutide	Terlipressin
Германия	Не одобрено	Рецептурный
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Glepaglutide and Terlipressin?: Glepaglutide is classified as "Исследования (прочее)", while Terlipressin is classified as "Исследования (прочее)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Terlipressin?: The highest available evidence level is "РКИ на людях" for Glepaglutide and "РКИ на людях" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Terlipressin in Germany and the United States?: Германия: Glepaglutide — Не одобрено, Terlipressin — Рецептурный. США: Glepaglutide — Не одобрено, Terlipressin — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Terlipressin

Германия

Не одобрено

Рецептурный

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Glepaglutide and Terlipressin?

Glepaglutide is classified as "Исследования (прочее)", while Terlipressin is classified as "Исследования (прочее)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Terlipressin: Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Terlipressin?

The highest available evidence level is "РКИ на людях" for Glepaglutide and "РКИ на людях" for Terlipressin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Terlipressin in Germany and the United States?

Германия: Glepaglutide — Не одобрено, Terlipressin — Рецептурный. США: Glepaglutide — Не одобрено, Terlipressin — Рецептурный. These are factual summaries with source and review date on the individual pages.